Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;38(12):1420-4.
doi: 10.1016/j.leukres.2014.09.011. Epub 2014 Sep 30.

Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS)

Hajime Uno  1 , Angel M Cronin  1 , Martha Wadleigh  2 , Deborah Schrag  1 , Gregory A Abel  3
Affiliations

Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS)

Hajime Uno et al. Leuk Res. 2014 Dec.

Abstract

Accruing data since 2001, the SEER-Medicare dataset is an outstanding resource for MDS-related comparative effectiveness research; however, although several MDS prognostic models exist, complete data required to calculate them are not available therein. Using SEER-Medicare as a training and internal validation set (n=9820) and clinical data at our institution as an external validation set (n=307), we created a new MDS risk score (the SMMRS) for use with SEER-Medicare. Risk stratification by the SMMRS was comparable to the IPSS (net reclassification improvement index was 0.0), demonstrating that it is a useful research tool to stratify MDS patients in studies using SEER-Medicare.

Keywords: Comparative effectiveness; MDS; Prognosis; SEER; SEER-Medicare.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall Survival by Risk Score with DFCI CRIS Data (NB: Kaplan-Meier curves for low risk (red), intermediate-1 (orange), intermediate-2 (green), and high (blue) by each stratification system)
See this image and copyright information in PMC

References

    1. Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011 Jun 30;117(26):7121–7125. - PMC - PubMed
    1. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007 Apr 15;109(8):1536–1542. - PubMed
    1. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008 Jul 1;112(1):45–52. - PubMed
    1. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–40. - PubMed
    1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32. - PMC - PubMed

Publication types